Argent Biopharma (RGT) Price & Analysis

Compare

6 Followers

RGT Stock Chart & Stats

AU$0.08

>-AU$0.01(-2.00%)

At close: Jan 08 4:00 PM EST

AU$0.08

>-AU$0.01(-2.00%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.32

Previous CloseN/A

Volume362.25K

Average Volume (3M)77.74K

Market Cap

AU$4.78M

Enterprise ValueAU$12.04M

Total Cash (Recent Filing)AU$1.02M

Total Debt (Recent Filing)AU$8.29M

Price to Earnings (P/E)―

Beta-1.33

Next Earnings

Feb 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding86,942,314

10 Day Avg. Volume131,422

30 Day Avg. Volume77,736

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improved Gross Margin (2025)A material gross-margin improvement in 2025 signals better product mix or pricing and indicates the company can extract more value from sales. If sustained, higher gross margins create structural room to absorb fixed costs and move toward profitability as revenue stabilizes.

Less-negative Free Cash Flow (2025)An improvement in free cash flow, even if still negative, reflects progress in cash conversion or cost control. Durable reductions in cash burn lengthen runway, reduce near-term financing needs and lower dilution risk, improving the company’s ability to self-fund operations over months.

EPS Growth TrendPositive EPS growth indicates improving per-share earnings dynamics despite headline losses. When paired with rising gross margin and FCF improvement, EPS growth suggests operational leverage or structural cost actions by management that, if maintained, support a sustainable recovery in profitability.

Bears Say

Sharp Revenue ContractionA steep multi-year revenue decline destroys scale critical for specialty drug makers. Lower top-line volume undermines ability to spread R&D and fixed costs, making margin improvements harder to convert into profits and threatening long-term commercial viability without revenue recovery.

Negative Shareholders' Equity And Rising LeverageNegative equity and increasing debt materially weaken financial resilience and flexibility. This structural leverage raises refinancing and solvency risk, increases financing costs or dilution likelihood, and constrains the company’s ability to invest in growth or withstand prolonged setbacks.

Consistent Cash Burn; Zero Operating Cash FlowPersistent negative FCF and nil operating cash flow show the business cannot self-fund operations. Continued cash burn forces repeated external funding, increasing dilution or debt, and places structural pressure on execution and R&D investment unless cash generation sustainably reverses.

Argent Biopharma News

Argent BioPharma Files U.S. Provisional Patent for NanoBodies Platform Targeting Septic Shock

Argent Biopharma ( ($AU:RGT) ) has provided an announcement. Argent BioPharma has filed a U.S. provisional patent application...

23h ago

Argent BioPharma Clears Compliance Path for New Share Issue

Argent Biopharma ( ($AU:RGT) ) has shared an announcement. Argent BioPharma has issued 2,557,450 fully paid ordinary shares...

16d ago

Argent Biopharma Seeks ASX Quotation for Over 2.5 Million New Shares

Argent Biopharma ( ($AU:RGT) ) has shared an announcement. Argent Biopharma Limited has applied to the ASX for...

16d ago

Argent BioPharma Clears 1 Million New Shares for On‑Sale Under Corporations Act Exemption

Argent Biopharma ( ($AU:RGT) ) has issued an announcement. Argent BioPharma has issued 1,000,000 fully paid ordinary shares...

1M ago

Argent Biopharma Seeks Quotation of 1 Million New Shares on ASX

Argent Biopharma ( ($AU:RGT) ) has issued an update. Argent Biopharma Limited, listed on the ASX under the...

1M ago

Argent Biopharma Plans Placement of Up to 20 Million New Shares

Argent Biopharma ( ($AU:RGT) ) has provided an announcement. Argent Biopharma Limited has notified the ASX of its...

1M ago

Argent BioPharma Streamlines AusCann Deal to Bolster CannEpil and IP Portfolio

An update from Argent Biopharma ( ($AU:RGT) ) is now available. Argent BioPharma has signed a binding agreement...

1M ago

Argent BioPharma Issues New Shares to Support Clinical Advancements

Argent Biopharma ( ($AU:RGT) ) has issued an announcement. Argent BioPharma has issued 5,616,000 fully paid ordinary shares,...

3M ago

Argent Biopharma Issues Employee Incentive Securities

Argent Biopharma ( ($AU:RGT) ) has shared an update. Argent Biopharma Limited has announced the issuance of 5,000,000...

3M ago

Argent Biopharma Issues New Securities to Creditors

Argent Biopharma ( ($AU:RGT) ) just unveiled an announcement. Argent Biopharma Limited announced the issuance of 616,000 ordinary...

3M ago

RGT FAQ

What was Argent Biopharma’s price range in the past 12 months?

Argent Biopharma lowest share price was AU$0.05 and its highest was AU$0.32 in the past 12 months.

What is Argent Biopharma’s market cap?

Argent Biopharma’s market cap is AU$4.78M.

When is Argent Biopharma’s upcoming earnings report date?

Argent Biopharma’s upcoming earnings report date is Feb 27, 2026 which is in 2 days.

How were Argent Biopharma’s earnings last quarter?

Argent Biopharma released its earnings results on Aug 29, 2025. The company reported -AU$0.079 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.079.

Is Argent Biopharma overvalued?

According to Wall Street analysts Argent Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Argent Biopharma pay dividends?

Argent Biopharma does not currently pay dividends.

What is Argent Biopharma’s EPS estimate?

Argent Biopharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Argent Biopharma have?

Argent Biopharma has 86,942,314 shares outstanding.

What happened to Argent Biopharma’s price movement after its last earnings report?

Argent Biopharma reported an EPS of -AU$0.079 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.704%.

Which hedge fund is a major shareholder of Argent Biopharma?

Currently, no hedge funds are holding shares in AU:RGT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Argent Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-77.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Argent Biopharma

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.